Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

Companies, including healthcare entities, are responsible for complying with new and existing California laws and must take full accountability for their actions, decisions, and products.” ...

$10,000 of CYTOKINETICS INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "General healthcare representation.

Cytokinetics has been a top biotech takeover candidate for some time, thanks to blockbuster speculation about its lead drug aficamten, but a $1 billion-plus set of financing deals shows it is ...

Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Amnesty International reported severe systematic human rights violations in Azerbaijan on Thursday. The report reflects the lack of improvement and the systemic nature of the abuses, including ...

The week's most popular albums on independent labels, as compiled by Luminate, based on multi-metric consumption blending traditional album sales, track equivalent albums and streaming (audio ...

Here below you have a complete description of its most interesting features and benefits so you can make the most of it. The majority of other information websites display prices of a single ...

THE WEEK’S MOST POPULAR SONGS RANKED BY ALL-FORMAT RADIO AIRPLAY AUDIENCE IMPRESSIONS, AS MEASURED BY MEDIABASE AND PROVIDED BY LUMINATE. Shaboozey Last week Weeks at no. 1 Weeks on chart C.O ...